Surpass-Early randomized ~800 adults with ≤4-year type 2 diabetes on metformin to add tirzepatide or intensify care, predominantly with semaglutide or dulaglutide comparators. At two years, ...
Priority therapeutic candidates for Bundibugyo Ebola include MBP134, maftivimab, and remdesivir, reflecting the absence of licensed strain-specific countermeasures. Field availability of maftivimab in ...
Zepbound’s return as a preferred option reverses a prior formulary exclusion that maintained Wegovy coverage, underscoring how net pricing and rebate contracting drive PBM obesity access decisions.
In today’s Pharmaceutical Executive Daily, an FDA advisory committee weighs recommendations for the composition of the 2026–2027 Covid-19 vaccines, CVS Health restores coverage for Eli Lilly’s ...
VRBPAC is evaluating an XFG-targeted composition for 2026–2027 vaccines, based on CDC variant prevalence estimates that are more than a month old. FDA briefing materials emphasize eroding sequencing ...
Chronic HDV occurs only with HBV and confers markedly higher risks of rapid progression, cirrhosis, liver failure, and ...
Makary’s departure followed internal disputes over approval decisions and Covid-19 vaccine posture, catalyzing a rapid ...
Positioning shifts from treatment to prophylaxis, using vaccines to blunt antimicrobial resistance-driven unmet need and mitigate infection-associated long-term morbidity, including neurological ...
Regeneron and Parabilis Medicines partner to discover and develop antibody-Helicon conjugates, aiming to create a new class ...
The Incyte–Genesis deal pairs significant upfront capital with long-tail milestones and royalties, while granting Incyte ...
Dr. Richard Graham explains how FDA’s new program allows for the usage of real-time data during clinical trials. In April, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results